Richard L. Dunbar

Biography

Dr. Richard L. Dunbar is affiliated to Department of Medicine, The University of Pennsylvania Health System. Dr. Richard L. Dunbar is currently providing services as Assistant Professor. Dr. Richard L. Dunbar authored and co-authored multiple atherogenic dyslipidemia and its treatment, and has particular expertise in the mechanism of action and adverse effects of triglyceride-lowering drugs. He has worked with a variety of several novel triglyceride-lowering compounds, including niacin and novel niacin mimetics, fibrates and novel fibrates, novel fish oils, and a host of other emerging drugs: DGAT-1 inhibitor, MTP inhibitor, AngPTL3 inhibitor, ApoC3 inhibitor, a glitazar, and perhaps most uniquely, lipoprotein lipase gene replacement therapy. He also employs a variety of provoked outcomes in his research, such as oral fat tolerance testing with/without radiolabeled fat to trace chylomicrons, stable isotope lipoprotein kinetics, euglycemic-hyperinsulinemic clamp, FSIVGTT, indocyanine green to test hepatic function, other nutrient challenges, and a variety of modalities to measure niacin-associated skin toxicity. A common theme of these is the concept that perturbing a system reveals more as an outcome than the steady state. His research focuses on translating pre-clinical findings into humans, and indeed works exclusively on patient-oriented, clinical research..

Research Interest

atherogenic dyslipidemia and its treatment, and has particular expertise in the mechanism of action and adverse effects of triglyceride-lowering drugs. He has worked with a variety of several novel triglyceride-lowering compounds, including niacin and novel niacin mimetics, fibrates and novel fibrates, novel fish oils, and a host of other emerging drugs: DGAT-1 inhibitor, MTP inhibitor, AngPTL3 inhibitor, ApoC3 inhibitor, a glitazar, and perhaps most uniquely, lipoprotein lipase gene replacement therapy. He also employs a variety of provoked outcomes in his research, such as oral fat tolerance testing with/without radiolabeled fat to trace chylomicrons, stable isotope lipoprotein kinetics, euglycemic-hyperinsulinemic clamp, FSIVGTT, indocyanine green to test hepatic function, other nutrient challenges, and a variety of modalities to measure niacin-associated skin toxicity. A common theme of these is the concept that perturbing a system reveals more as an outcome than the steady state. His research focuses on translating pre-clinical findings into humans, and indeed works exclusively on patient-oriented, clinical research.